BR112022010908A2 - Métodos para aumentar a permeabilidade da barreira hematoencefálica, para distribuir um agente terapêutico ao cérebro e para identificar uma biomolécula que regula a permeabilidade da barreira hematoencefálica em um sujeito - Google Patents
Métodos para aumentar a permeabilidade da barreira hematoencefálica, para distribuir um agente terapêutico ao cérebro e para identificar uma biomolécula que regula a permeabilidade da barreira hematoencefálica em um sujeitoInfo
- Publication number
- BR112022010908A2 BR112022010908A2 BR112022010908A BR112022010908A BR112022010908A2 BR 112022010908 A2 BR112022010908 A2 BR 112022010908A2 BR 112022010908 A BR112022010908 A BR 112022010908A BR 112022010908 A BR112022010908 A BR 112022010908A BR 112022010908 A2 BR112022010908 A2 BR 112022010908A2
- Authority
- BR
- Brazil
- Prior art keywords
- brain barrier
- barrier permeability
- blood
- brain
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
MÉTODOS PARA AUMENTAR A PERMEABILIDADE DA BARREIRA HEMATOENCEFÁLICA, PARA DISTRIBUIR UM AGENTE TERAPÊUTICO AO CÉREBRO E PARA IDENTIFICAR UMA BIOMOLÉCULA QUE REGULA A PERMEABILIDADE DA BARREIRA HEMATOENCEFÁLICA EM UM SUJEITO. São fornecidos, neste documento, métodos e composições para aumentar a permeabilidade da barreira hematoencefálica em um sujeito para melhorar o transporte de fármacos pela barreira hematoencefálica e métodos e composição para identificar agentes que regulam a permeabilidade da barreira hematoencefálica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943610P | 2019-12-04 | 2019-12-04 | |
US202063044048P | 2020-06-25 | 2020-06-25 | |
PCT/US2020/063112 WO2021113512A1 (en) | 2019-12-04 | 2020-12-03 | Enhancing blood-brain barrier drug transport by targeting endogenous regulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022010908A2 true BR112022010908A2 (pt) | 2022-09-06 |
Family
ID=76222260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022010908A BR112022010908A2 (pt) | 2019-12-04 | 2020-12-03 | Métodos para aumentar a permeabilidade da barreira hematoencefálica, para distribuir um agente terapêutico ao cérebro e para identificar uma biomolécula que regula a permeabilidade da barreira hematoencefálica em um sujeito |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230257480A1 (pt) |
EP (1) | EP4069368A4 (pt) |
JP (1) | JP2023504191A (pt) |
KR (1) | KR20220110263A (pt) |
CN (1) | CN114929338A (pt) |
AU (1) | AU2020398216A1 (pt) |
BR (1) | BR112022010908A2 (pt) |
CA (1) | CA3160600A1 (pt) |
IL (1) | IL293545A (pt) |
WO (1) | WO2021113512A1 (pt) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
WO1989011299A1 (en) | 1988-05-18 | 1989-11-30 | State Of Oregon Acting By And Through The State Bo | Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates |
CA2163966A1 (en) * | 1993-06-01 | 1994-12-08 | Judith A. Kelleher | Alkaline and acid phosphatase inhibitors in treatment of neurological disorders |
JP2001238681A (ja) | 2000-03-03 | 2001-09-04 | Japan Science & Technology Corp | 共培養による血液脳関門再構築モデル |
WO2004056386A2 (en) * | 2002-12-19 | 2004-07-08 | To-Bbb Holding B.V. | Nucleic acids involved in blood-brain barrier control |
EP2274007B1 (en) | 2008-03-10 | 2016-12-14 | Cornell University | Modulation of blood brain barrier permeability |
AU2009226161A1 (en) | 2008-03-21 | 2009-09-24 | Adlyfe, Inc. | Use of pyrene to carry peptides across the blood brain barrier |
US20130224110A1 (en) | 2010-09-16 | 2013-08-29 | Cornell University | Use of adenosine receptor signaling to modulate permeability of blood-brain barrier |
US9458147B2 (en) | 2012-02-22 | 2016-10-04 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
EP3137101A2 (en) * | 2014-04-30 | 2017-03-08 | Amrif B.V. | The application of rescap to attenuate and prevent the progression of neurodegenerative brain and neuronal diseases |
GB2563899A (en) * | 2017-06-29 | 2019-01-02 | Ernst Ludwig Georg Muller Werner | Inorganic polyphosphate formulations for use in the treatment of Alzheimer disease |
-
2020
- 2020-12-03 AU AU2020398216A patent/AU2020398216A1/en active Pending
- 2020-12-03 KR KR1020227022660A patent/KR20220110263A/ko unknown
- 2020-12-03 CN CN202080091813.XA patent/CN114929338A/zh active Pending
- 2020-12-03 US US17/782,501 patent/US20230257480A1/en active Pending
- 2020-12-03 JP JP2022534162A patent/JP2023504191A/ja active Pending
- 2020-12-03 BR BR112022010908A patent/BR112022010908A2/pt unknown
- 2020-12-03 CA CA3160600A patent/CA3160600A1/en active Pending
- 2020-12-03 IL IL293545A patent/IL293545A/en unknown
- 2020-12-03 EP EP20896434.6A patent/EP4069368A4/en active Pending
- 2020-12-03 WO PCT/US2020/063112 patent/WO2021113512A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3160600A1 (en) | 2021-06-10 |
CN114929338A (zh) | 2022-08-19 |
IL293545A (en) | 2022-08-01 |
AU2020398216A1 (en) | 2022-06-30 |
EP4069368A1 (en) | 2022-10-12 |
WO2021113512A1 (en) | 2021-06-10 |
JP2023504191A (ja) | 2023-02-01 |
EP4069368A4 (en) | 2023-08-09 |
US20230257480A1 (en) | 2023-08-17 |
KR20220110263A (ko) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002018A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
BR112018003984A2 (pt) | anticorpos | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
BR112016022345A2 (pt) | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 | |
BR122021018243A8 (pt) | Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável | |
BR112019001794A2 (pt) | composição de cannabis | |
CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
BR112017006531A2 (pt) | composições, kits e métodos para induzir citorresistência adquirida utilizando indutores de proteínas de estresse | |
BR112016006048A8 (pt) | composições antimicrobianas | |
UY37818A (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
CR20150505A (es) | Derivado de dihidropiridazin-3,5-diona | |
BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
BR112014030279A2 (pt) | métodos para tratamento de neutropenia usando agonistas retinóide | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
BR112017028137A2 (pt) | agente terapêutico para fibrose | |
BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
BR112019001130A2 (pt) | uso de lactama e composição farmacêutica | |
CY1122979T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης | |
BR112022010908A2 (pt) | Métodos para aumentar a permeabilidade da barreira hematoencefálica, para distribuir um agente terapêutico ao cérebro e para identificar uma biomolécula que regula a permeabilidade da barreira hematoencefálica em um sujeito | |
BR112017004552A2 (pt) | composições farmacêuticas | |
PE20200749A1 (es) | Moduladores de la expresion de enac |